Insurance barriers were the top reason 4 in 10 people prescribed long-acting PrEP at a Missouri clinic never received it, an IDWeek 2026 poster found.
|Articles|May 31, 2019
Managing Vaso-Occlusive Crisis in Sickle Cell Disease: A Look at the Clinical and Economic Burden
https://www.pharmacytimes.org/on-demand/managing-vasoocclusive-crisis-in-sickle-cell-disease-a-look-at-the-clinical-and-economic-burden
Advertisement
Advertisement
Related to this article
A retrospective study suggests strength exercise may be a safer option than endurance exercise for some people with ACM.
Infant flu protection from maternal vaccination varied by timing, while pediatric vaccination fell to 49.4%, experts report at IDWeek 2026.
The NCCN’s latest esophageal/EGJ guidance raises durvalumab plus FLOT to a category 2A recommendation for PD-L1–negative, diffuse-type disease.
Legal and clinical experts examined the US medical aid in dying framework, its limits, and ethical debates.
The pilot pairs grocery stipends and community health worker support with members who have unmanaged diabetes and unmet social needs.
Speakers at IDWeek 2026 urged shifting global health partnerships from donor-recipient models to shared, locally led ownership as funding contracts.
Insmed launches once-daily brensocatib in Japan, the country's only approved treatment for noncystic fibrosis bronchiectasis.
Advertisement
Advertisement
Trending on AJMC
1
Extension Studies in TPIP Show Promise in PAH, PH-ILD
2
Bepirovirsen Approval Offers New Option for Chronic HBV Treatment
3
Inhaled Amikacin Raises Culture Conversion in New MAC Lung Disease
4
Bronchiectasis GWAS Highlights Candidate Targets Shared With COPD
5